Clinical Trials

Breast Neoplasms

NCT03839459 2026-01-28

Denosumab for Smoldering Multiple Myeloma

Phase 3 Active not recruiting

20 enrolled 8 charts

Plasma cell

Smoldering Multiple Myeloma

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

1,380 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04549207 2025-11-28

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Phase 4 Active not recruiting

240 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT04067726 2025-10-16

TRIDENT

210 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06513624 2025-07-25

ETC-159-02

Phase 1 Recruiting

16 enrolled

Gynecologic

With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

NCT07043608 2025-07-02

ZAMBONI

20 enrolled

Phase 3 Active not recruiting

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT03958565 2025-05-21

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Recruiting

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04711109 2025-04-02

BRCA-P

300 enrolled

Breast Diseases, Breast Neoplasms, Neoplasms

NCT03792763 2025-02-11

DEFENCE

Phase EARLY_PHASE1 Completed

8 enrolled

Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06749886 2024-12-27

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

Phase 2 Recruiting

22 enrolled

Thoracic

Lung Neoplasms

NCT03629717 2024-10-16

RANKL Inhibition and Breast Tissue Biomarkers

10 enrolled

Breast Neoplasms

NCT03620019 2024-08-12

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Phase 3 Not yet recruiting

25 enrolled 16 charts

Dermatologic

Melanoma

NCT03401060 2024-05-03

DenosuMast

Phase 3 Completed

24 enrolled

Myeloid

Osteoporosis, Mastocytosis, Systemic

NCT06314698 2024-03-18

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

478 enrolled

Plasma cell

Bone Diseases, Multiple Myeloma

NCT03324932 2023-10-06

Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

Phase 3 Active not recruiting

160 enrolled

Breast Neoplasms

NCT03280667 2023-03-29

KEYPAD

Phase 2 Unknown

59 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05435768 2022-08-18

PRaG 2X

Unknown

51 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03161756 2022-04-07

CHARLI

Phase 1/2 Unknown

72 enrolled

Dermatologic

Melanoma

NCT03732495 2022-03-29

LENVOS

Phase 2 Unknown

35 enrolled

EndocrineHead & Neck

Thyroid Cancer Metastatic

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT03408652 2021-10-22

MOSCAR

Phase 3 Terminated

1 enrolled

Carcinoma, Renal Cell

NCT02366130 2021-10-07

Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer

45 enrolled 7 charts

Breast Neoplasms

NCT03027557 2021-05-25

DENOCINA

Phase 3 Completed

46 enrolled 49 charts

Head & Neck

Parathyroid Neoplasms, Hyperparathyroidism, Primary

NCT01624766 2021-02-25

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

Phase 1 Completed

57 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT02682693 2021-02-02

GeparX

780 enrolled

Phase EARLY_PHASE1 Completed

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT02900469 2020-08-21

Presurgical Trial of Denosumab in Breast Cancer

44 enrolled

Breast Neoplasms

NCT01545648 2020-01-02

Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

4 enrolled 7 charts

Tumor-Agnostic

Neoplasms

NCT01952054 2019-11-22

Denosumab for Breast Cancer With Bone Mets

7 enrolled 8 charts

Breast Neoplasms

NCT02758132 2019-11-08

Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases

1 enrolled 7 charts

Prostatic Neoplasms

NCT03605199 2019-08-26

Denosumab in Subjects With Giant Cell Rich Tumors of Bone

Phase 2 Unknown

60 enrolled

Chondroblastoma, Granuloma, Giant Cell, Bone Cysts, Aneurysmal, Osteoblastoma

NCT03811509 2019-01-28

B-ABLE

Phase 4 Unknown

1,000 enrolled

Breast Neoplasms, Osteoporosis, Arthralgia, Osteoporotic Fractures, Musculoskeletal Pain

NCT01864798 2018-11-27

D-Beyond

27 enrolled

Breast Neoplasms

NCT03070002 2018-11-20

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

1 enrolled 6 charts